ClinicalTrials.gg

Program

Arginine

Also written as “8% arginine + Zinc toothpaste”, “arginine/lysine” and “L Arginine”.

Its studies are mostly in Dental Caries · Dentin Sensitivity · Gastro-enteropancreatic neuroendocrine tumor · Peripheral Vascular Diseases · Peripheral Arterial Disease, led by 4 companies.

Furthest: phase 4, since Jun 18, 20267 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Colgate Palmolive31 open or runningphase 3since Jun 18, 2026Feb 4, 2015none ahead
POLYSAN Scientific & Technological Pharmaceutical20 open or runningphase 2since Mar 1, 2019Jan 16, 2017none ahead
Novartis10 open or runningphase 4since Aug 20, 2020Aug 20, 2020none ahead
Pfizer10 open or runningno phasesince Jan 18, 2006Jan 18, 2006none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 18, 2006First study: no phase study in Diabetes MellitusNew to PfizerPfizer · NCT00280085 · 29 enrolled · United States
  2. Feb 4, 2015Colgate Palmolive's first study: phase 2 study in Dental CariesNew to Colgate PalmoliveColgate Palmolive · NCT02388178
  3. Jan 16, 2017POLYSAN Scientific & Technological Pharmaceutical's first study: phase 1 study in Peripheral Vascular DiseasesNew to POLYSAN Scientific & Technological PharmaceuticalPOLYSAN Scientific & Technological Pharmaceutical · NCT03028285 · 48 enrolled · Russian Federation
  4. Mar 1, 2019Phase 2 study in Peripheral Arterial DiseasePOLYSAN Scientific & Technological Pharmaceutical · NCT03861416 · 360 enrolled · Russian Federation
  5. Aug 20, 2020Novartis's first study: phase 4 study in Gastro-enteropancreatic neuroendocrine tumorNew to NovartisNovartis · NCT04524442 · 42 enrolled · Italy, Netherlands, Poland and more
  6. Dec 13, 2023Phase 1 study in Dental CariesColgate Palmolive · NCT06182267 · 29 enrolled · United States
  7. Jun 18, 2026Phase 3 study in Dentin SensitivityPhase 3 reachedColgate Palmolive · NCT07664592 · 132 planned · Brazil

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07664592Dentin Sensitivity · Brazil3RecruitingColgate PalmoliveSep 2026132
NCT06182267Dental Caries · United States1CompletedColgate PalmoliveDec 22, 202329
NCT04524442Gastro-enteropancreatic neuroendocrine tumor · Italy, Netherlands, Poland and more4CompletedNovartisNov 18, 202342
NCT03861416Peripheral Arterial Disease · Russian Federation2CompletedPOLYSAN Scientific & Technological PharmaceuticalSep 13, 2019360
NCT03028285Peripheral Vascular Diseases · Russian Federation1CompletedPOLYSAN Scientific & Technological PharmaceuticalJan 19, 201748
NCT02388178Dental Caries2WithdrawnColgate PalmoliveJul 20150
NCT00280085Diabetes Mellitus · United States–TerminatedPfizer29

How it is read

Names in the registry

  • “8% arginine + Zinc toothpaste”, 1 entry
  • “arginine/lysine”, 1 entry
  • “L Arginine”, 1 entry
  • “Experimental toothpaste containing fluoride and amino acid (arginine)”, 1 entry
  • “arginine sodium succinate”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.